Summary: Host: Richard S. Isaacson, MD <br> Guest: Pierre N. Tariot, MD <br> Guest: Gayatri Devi, MD, MS, FAAN, FACP <br> <p>Alzheimer’s Disease (AD) has historically been a condition associated with more questions than answers. These questions are only increasing with the flurry of developmental activity in recent years, particularly the introduction of the first ever disease modifying therapies, as the clinical picture is dramatically changing each day. To help address rising challenges prompted by this shifting paradigm, this activity features real questions from practicing clinicians regarding the integration of and expert perspectives on amyloid-targeting therapies for the treatment of AD. </p> <p>Note: This program was recorded prior to the January 31, 2024 decision to withdraw aducanumab from the market. Though amyloid targeting therapy is available, this particular agent can no longer be prescribed. For more information, see: <u><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__investors.biogen.com_news-2Dreleases_news-2Drelease-2Ddetails_biogen-2Drealign-2Dresources-2Dalzheimers-2Ddisease-2Dfranchise&d=DwMGaQ&c=euGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM&r=ESORFHgytGWk7-s4-WASR1DLzjMACYvZa08aiORc7fU&m=C8jdP5mjzBCvyE3dWErPFA1JaZHYAgsZWcV0871SokzVEg-Bdl9mN3DQi57wCA-J&s=qThh272wMJow7ZKUzm0jyhOPMHUbJG4Fv_zxNWRzduo&e=" target="_blank" rel="noopener" data-linkindex="0" data-auth="NotApplicable">https://investors.biogen.com/news-releases/news-release-details/biogen-realign-resources-alzheimers-disease-franchise</a></u></p>
